Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amaia Calderón-Larrañaga.png

Post Doc researcher EpiChron Research Group on Chronic Diseases 

Amaia Calderón-Larrañaga, MPH, PhD. Member of the EpiChron Research Group on Chronic Diseases from the Aragon Health Sciences Institute (IACS) since 2008 and the Spanish Chronic Disease Health Services Research Network (REDISSEC) since 2012. Associate Professor at the Department of Microbiology, Preventive Medicine and Public Health of the University of Zaragoza.

She has participated in several collaborative projects with the Department of Primary Care and Public Health of Imperial College London, the ACG Team of Johns Hopkins Bloomberg School of Public Health, and the Department of General Practice of Maastricht University. Currently, she is involved as an epidemiologist in a national research project funded by the Spanish Ministry of Economy and Competitiveness focused on increasing understanding of the complex healthcare needs of the primary care population.

During her professional trajectory within the EpiChron group, Amaia has become knowledgeable on core competencies of primary care research (person-centred care, comprehensive and holistic approach), assessment of health status (multimorbidity, patient complexity, social determinants), health services research methodology (ethics, data quality assessment, study design, innovative analysis strategies), and multidisciplinary research (team work, leadership, chairing capacity).

The ultimate purpose of her research activity is to translate epidemiological knowledge into improved healthcare delivery for primary care patients with multiple chronic conditions by developing future intervention programs aimed at reducing the adverse health consequences associated with multimorbidity and polypharmacy. This will be one of the critical public health challenges of the 21st century.